Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.41 |
| ▸ | MME | P08473 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.39 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.39 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.39 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | PAM | P19021 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.37 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.37 |
| ▸ | ITGAV | P06756 | 1/20 | 0.37 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15315079 | 1.00 | CA2 (0.43) | CA2NPC1RAB9ASOAT1MME | |
| SCHEMBL24286177 | 0.89 | CA2 (0.43) | CA2NPC1RAB9ASOAT1MME | |
| SCHEMBL30404207 | 0.86 | CA2 (0.52) | CA2NPC1RAB9ASOAT1MME | |
| SCHEMBL1093901 | 0.86 | CA2 (0.52) | CA2NPC1RAB9ASOAT1MME | |
| SCHEMBL1093903 | 0.86 | CA2 (0.52) | CA2NPC1RAB9ASOAT1MME | |
| SCHEMBL19679999 | 0.84 | ACACB (0.50) | NPC1RAB9AALDH1A1TSHREPHX1 | |
| SCHEMBL14898395 | 0.84 | ACACB (0.50) | NPC1RAB9AALDH1A1TSHREPHX1 | |
| SCHEMBL8231892 | 0.84 | ESR1 (0.56) | MMEESR1ESR2SLC7A5 | |
| SCHEMBL7637685 | 0.84 | ESR1 (0.56) | MMEESR1ESR2SLC7A5 | |
| SCHEMBL16327905 | 0.84 | ESR1 (0.40) | CA2MMEALDH1A1EPHX1ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340575-B2 | Agonists and antagonists of the urotensinergic system | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2016-05-17 | — | — | US | disclosed |
| US-8809278-B2 | Cyclic tetrapeptides | UNIVERSITY OF KANSAS (US) | 2014-08-19 | — | — | US | disclosed |
| US-8809278-B2 | Cyclic tetrapeptides | UNIVERSITY OF KANSAS (US) | 2014-08-19 | — | — | US | disclosed |
| EP-2376520-B1 | INSULIN ANALOGS | UNIV INDIANA RES & TECH CORP (US) | 2014-02-12 | — | — | EP | disclosed |
| US-8481485-B2 | Insulin analogs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-8481485-B2 | Insulin analogs | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120264693-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | ZEALAND PHARMA A/S (DK) | 2012-10-18 | — | — | US | disclosed |
| US-20110257091-A1 | INSULIN ANALOGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | disclosed |
| US-20110257091-A1 | INSULIN ANALOGS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION | 2011-10-20 | — | — | US | disclosed |
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2011-08-04 | — | — | US | disclosed |
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | ZEALAND PHARMA A/S (DK) | 2010-11-25 | — | — | US | disclosed |
| WO-2010006267-A2 | CYCLIC TETRAPEPTIDES | UNIVERSITY OF KANSAS (US) | 2010-01-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298225-A1 | PEPTIDE GAP JUNCTION MODULATORS | GJA1, GJB2, GAP43 | CA2 3292/4885NPC1 1499/4885RAB9A 743/4885 |
| US-20120264693-A1 | COMPOUNDS ACTING AS PEPTIDE GAP JUNCTION MODULATORS, AND USES THEREOF | GJA1, GJB2, GAP43 | CA2 3238/4885NPC1 1004/4885RAB9A 570/4885 |
| US-20110257091-A1 | INSULIN ANALOGS | IAPP, GPR119, INSR | CA2 4727/4885NPC1 4151/4885RAB9A 2205/4885 |
| US-20110190212-A1 | CYCLIC TETRAPEPTIDES | OPRK1, OPRL1, OPRD1 | CA2 4583/4885NPC1 3584/4885RAB9A 3747/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.